Evaluating non-randomised intervention studies.

JJ Deeks, J Dinnes, R D'Amico… - Health technology …, 2003 - researchonline.lshtm.ac.uk
OBJECTIVES: To consider methods and related evidence for evaluating bias in non-
randomised intervention studies. DATA SOURCES: Systematic reviews and methodological …

Delirium in the ICU: an overview

R Cavallazzi, M Saad, PE Marik - Annals of intensive care, 2012 - Springer
Delirium is characterized by a disturbance of consciousness with accompanying change in
cognition. Delirium typically manifests as a constellation of symptoms with an acute onset …

ACG clinical guideline: alcohol-associated liver disease

LL Jophlin, AK Singal, R Bataller… - Official journal of the …, 2024 - journals.lww.com
Alcohol-associated liver disease (ALD) is the most common cause of advanced hepatic
disease and frequent indication for liver transplantation worldwide. With harmful alcohol use …

ACG clinical guideline: alcoholic liver disease

AK Singal, R Bataller, J Ahn, PS Kamath… - Official journal of the …, 2018 - journals.lww.com
Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver,
alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at …

[HTML][HTML] EASL clinical practical guidelines: management of alcoholic liver disease

European Association For The Study Of The Liver - Journal of hepatology, 2012 - Elsevier
Alcoholic liver disease (ALD) is the most prevalent cause of advanced liver disease in
Europe. However, there has been limited research investment into ALD despite its …

Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine

SC Pradhan, C Girish - Indian journal of medical research, 2006 - journals.lww.com
Silymarin, a flavonolignan from′ milk thistle′(Silybum marianum) plant is used almost
exclusively for hepatoprotection and amounts to 180 million US dollars business in Germany …

Prevention, screening, and treatment for heavy drinking and alcohol use disorder

J Knox, DS Hasin, FRR Larson, HR Kranzler - The Lancet Psychiatry, 2019 - thelancet.com
Heavy drinking and alcohol use disorder are major public health problems. Practitioners not
specialising in alcohol treatment are often unaware of the guidelines for preventing …

Identification and management of alcohol withdrawal syndrome

A Mirijello, C D'Angelo, A Ferrulli, G Vassallo… - Drugs, 2015 - Springer
Symptoms of alcohol withdrawal syndrome (AWS) may develop within 6–24 h after the
abrupt discontinuation or decrease of alcohol consumption. Symptoms can vary from …

Unhealthy alcohol use

R Saitz - New England Journal of Medicine, 2005 - Mass Medical Soc
Foreword This Journal feature begins with a case vignette highlighting a common clinical
problem. Evidence supporting various strategies is then presented, followed by a review of …

Management of drug and alcohol withdrawal

TR Kosten, PG O'Connor - New England Journal of Medicine, 2003 - Mass Medical Soc
This review summarizes the current approaches to the management of withdrawal in
patients addicted to sedatives such as alcohol or benzodiazepines, opioids, or stimulants …